Rifampicin-Amlodipine Interaction: A Case Report of Hypertension Exacerbation
Introduction: Rifampicin, a first-line anti-tubercular therapy drug, is a strong inducer of hepatic cytochrome P450 (CYP). Amlodipine and metoprolol, two anti-hypertensives that are CYP substrates, have the potential to interact pharmacologically with rifampicin. Therefore, individuals with hypertension receiving rifampicin-based anti-tubercular therapy are at risk for worsening hypertension.
Case Details: We report a case of a 63-year-old female patient, who developed accelerated hypertension after initiating rifampicin. Later, up to four antihypertensive drugs were administered as part of a gradual increase in dosage but did not successfully lower blood pressure to a desirable level. After clinical pharmacist intervention, Tab. Amlodipine+Metoprolol 5 mg+50 mg was discontinued and the blood pressure measurements gradually improved.
Conclusion: We postulate that rifampicin diminished the therapeutic effect of amlodipine and metoprolol and hence recommend that prudent monitoring for worsening hypertension should be carried out in hypertensive patients with chronic kidney disease receiving anti-tubercular therapy.
Alemu, A., Bitew, Z. W., Diriba, G., Seid, G., Eshetu, K., Chekol, M. T & Gumi, B. (2022). Tuberculosis incidence in patients with chronic kidney disease: a systematic review and meta-analysis. International Journal of Infectious Diseases.
Agrawal, A., Agarwal, S. K., Kaleekal, T., & Gupta, Y. K. (2016). Rifampicin and anti-hypertensive drugs in chronic kidney disease: Pharmacokinetic interactions and their clinical impact. Indian Journal of Nephrology, 26(5), 322.
Cordeanu, E. M., Gaertner, S., Faller, A., Mirea, C., Lessinger, J. M., Kemmel, V., & Stephan, D. (2017). Rifampicin reverses nicardipine effect inducing uncontrolled essential hypertension. Fundamental & Clinical Pharmacology, 31(5), 587-589.
Duggal, R. K., & Agrawal, G. P. (2019). Interaction of rifampicin with antihypertensive medications in chronic kidney disease patients: Clinical implications. Indian Journal of Medical Specialities, 10(3), 174.
Lee, S. L., Lim, W. J., & Chai, S. T. (2020). Resistant hypertension during antituberculosis treatment: how is rifampicin implicated?. Med J Malaysia, 75(5), 591.
Syed-Ahmed, M., & Narayanan, M. (2019). Immune dysfunction and risk of infection in chronic kidney disease. Advances in chronic kidney disease, 26(1), 8-15.
Copyright (c) 2023 Sinchana Bojamma P.K, Narne Akhil
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.